Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic
- Conditions
- COVID-19
- Interventions
- Drug: Convalescent Plasma Transfusion
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Qassim University
- Target Recruit Count
- 200
- Registration Number
- NCT04460547
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 221
- Registration Number
- NCT04385095
- Locations
- 🇬🇧
Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull, United Kingdom
🇬🇧City Campus of Nottingham University, Nottingham, United Kingdom
🇬🇧Belfast City Hospital, Belfast, United Kingdom
Interferon Beta 1a in Hospitalized COVID-19 Patients
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT04350671
- Locations
- 🇮🇷
Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT04343768
- Locations
- 🇮🇷
Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
Trial of Treatments for COVID-19 in Hospitalized Adults
- Conditions
- Corona Virus Infection
- Interventions
- Other: Standard of careOther: Placebo
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Target Recruit Count
- 1552
- Registration Number
- NCT04315948
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Martinique, Fort De France, France
🇫🇷Centre Hospitalier Andrée Rosemon, Cayenne, France
🇫🇷CHU APHP Ambroise-Paré, Boulogne-Billancourt, France
Study of Evobrutinib in Participants With RMS
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2021-08-05
- Target Recruit Count
- 1
- Registration Number
- NCT04032171
- Locations
- 🇺🇸
Please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪Please Contact the Communication Center, Darmstadt, Germany
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2021-08-05
- Target Recruit Count
- 3
- Registration Number
- NCT04032158
- Locations
- 🇺🇸
Please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪Please Contact the Communication Center, Darmstadt, Germany
Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 40
- Registration Number
- NCT03614715
- Locations
- 🇫🇮
CRST Oy, Clinical Research Services Turku Itäinen Pitkäkatu 4 B, 3rd floor, Turku, Finland
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Other: Placebo
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT03570359
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Celerion, Belfast, United Kingdom
🇬🇧Bradford Royal Infirmary, Bradford, United Kingdom
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT03177083
- Locations
- 🇵🇹
Hospital Fernando Fonseca, Amadora, Portugal
🇵🇹Hospital Evora, Evora, Portugal
🇵🇹Hospital de Braga, Braga, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.